GlassScriptPhysician profile
Abdul Ansari
NPI 1124655170
$3,389.50
in general payments reported to CMS, 2019-2025
12 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $31.19 · 2023: $620 · 2024: $876 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,259 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.31 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,754.12 | 2023-2025 | |
| Ucb, INC. | $274.46 | 2025 | Bimzelx |
| Genzyme Corporation | $228.84 | 2025 | |
| Amgen INC. | $203.50 | 2024-2025 | Otezla, Otezla |
| Incyte Corporation | $198.12 | 2024-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $182.08 | 2022-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $149.08 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $145.67 | 2025 | Ebglyss |
| Eli Lilly and Company | $99.00 | 2025 | |
| Botanix Sb INC | $74.26 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $56.30 | 2025 | |
| Blueprint Medicines Corporation | $24.07 | 2025 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.